7 completed, 4 active not recruiting, 3 recruiting, 3 terminated. 17 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 7, Active not recruiting 4, Recruiting 3, Terminated 3 |
| Phase 2 | 1 | Completed 1 |
Follow Myelofibrosis: new trials by email Literature Review of Myelofibrosis trials Research Report on Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib Placebo, Elritercept - Myelofibrosis, Anemia | Phase 3 | Recruiting | Takeda | 324 | 2026-09-10 | 2026-10-01 |
| Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib Navtemadlin, Navtemadlin placebo, Ruxolitinib - Myelofibrosis, Post-PV MF | Phase 3 | Recruiting | Kartos Therapeutics, Inc. | 600 | 2024-06-03 | 2025-09-25 |
| A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 400 | 2024-05-23 | 2026-04-02 |
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) parsaclisib, ruxolitinib, placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Terminated | Incyte Corporation | 177 | 2021-05-26 | 2025-10-02 |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) parsaclisib, ruxolitinib, placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Terminated | Incyte Corporation | 252 | 2021-05-24 | 2025-10-21 |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Imetelstat, Best Available Therapy (BAT) - Myelofibrosis | Phase 3 | Active not recruiting | Geron Corporation | 327 | 2021-04-12 | 2026-07-08 |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) Pelabresib, Ruxolitinib, Placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 430 | 2021-04-09 | 2026-07-17 |
| Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Selinexor, Placebo, Ruxolitinib - Myelofibrosis | Phase 3 | Active not recruiting | Karyopharm Therapeutics Inc | 353 | 2021-03-11 | 2026-10-01 |
| An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions ACE-536, Placebo - Myeloproliferative Disorders, Myelofibrosis | Phase 3 | Active not recruiting | Celgene | 313 | 2021-02-25 | 2026-07-16 |
| Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis Jaktinib, Placebo to match Hydroxycarbamide, Hydroxycarbamide Tablets - Myelofibrosis | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 105 | 2021-02-05 | 2023-11-13 |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib FEDRATINIB, Best Available Therapy (BAT) - Primary Myelofibrosis, Post-Polycythemia Vera | Phase 3 | Completed | Celgene | 202 | 2019-09-09 | 2025-08-28 |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib FEDRATINIB - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 3 | Terminated | Celgene | 38 | 2019-03-27 | 2024-12-12 |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia | Phase 3 | Completed | Dartmouth-Hitchcock Medical Center | 21 | 2018-03-28 | 2026-07-17 |
| INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. INC424 - Myelofibrosis | Phase 3 | Completed | Novartis Pharmaceuticals | 2233 | 2011-08-16 | 2019-04-26 |
| Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Ruxolitinib, Best Available Therapy (BAT) - Myelofibrosis | Phase 3 | Completed | Novartis Pharmaceuticals | 219 | 2009-07-01 | 2019-08-19 |
| Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Deferasirox - Thalassemia, Sickle Cell Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 1683 | 2005-10-01 | 2011-06-07 |
| Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant Alentuzumab, Globulina antilinfocitaria - Acute Myeloblastic Leukemia, Lymphoblastic Leukemia | Phase 2 / Phase 3 | Completed | Gruppo Italiano Trapianto di Midollo Osseo | 121 | 2005-03-01 | 2023-03-10 |
Primary Myelofibrosis (17) · Myeloproliferative Disorders (8) · Anemia (3) · Anemia, Refractory, with Excess of Blasts (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Acute (2) · Anemia, Diamond-Blackfan (1) · Anemia, Sickle Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms, Plasma Cell (1) · Polycythemia (1) · Polycythemia Vera (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Bone Marrow Diseases (17) · Hematologic Diseases (17) · Hemic and Lymphatic Diseases (17) · Myeloproliferative Disorders (9) · Neoplasms (3) · Anemia (2) · Anemia, Refractory (2) · Blood Platelet Disorders (2) · Chronic Disease (2) · Disease Attributes (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Leukemia, Myeloid (2)
ruxolitinib (7) · fedratinib (2) · parsaclisib (2) · Cyclophosphamide (1) · Deferasirox (1) · GRN163L peptide (1) · Granulocyte Colony-Stimulating Factor (1) · Hydroxyurea (1) · Mycophenolic Acid (1) · Tacrolimus (1) · Whole-Body Irradiation (1) · bomedemstat (1) · fludarabine (1) · imetelstat (1) · luspatercept (1)
Novartis Pharmaceuticals (4) · Celgene (3) · Incyte Corporation (2) · Dartmouth-Hitchcock Medical Center (1) · Geron Corporation (1) · Gruppo Italiano Trapianto di Midollo Osseo (1) · Kartos Therapeutics, Inc. (1) · Karyopharm Therapeutics Inc (1) · Merck Sharp & Dohme LLC (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1) · Takeda (1)
Italy (14) · Belgium (12) · Germany (12) · Spain (12) · United Kingdom (12) · United States (12) · Austria (10) · France (10) · Poland (10) · Hungary (9) · South Korea (9) · Australia (8) · Israel (8) · Canada (7) · Czechia (7)
Albert Assad, M.D (1) · Albert Assad, M.D. (1) · Alessandro Rambaldi, MD (1) · Jie Jin, PhD (1) · Joe Eid (1) · Kenneth Meehan, MD (1)
PMID 22375970, PMID 23911705, PMID 24056820, PMID 24174625, PMID 26069290, PMID 26380150, PMID 27247324, PMID 28962635, PMID 31235325, PMID 32017044, PMID 33210570, PMID 35510486, PMID 35950489, PMID 38838026, PMID 39265613, PMID 39695117, PMID 39911057, PMID 40065169, PMID 41785311, PMID 42227656
2023 (4), 2018 (2), 2009 (1)